Horimoto Yoshiya

Affiliation and department：

Research field (1)： Tumor diagnostics and therapeutics

Research theme for competitive and other funds (11)：

2022 - 2027 心筋ストレインと新規バイオマーカーによるがん治療関連心機能障害の予防と早期診断
2021 - 2024 The importance of NGLY1 on the chemoresistance of triple negative breast cancer
2019 - 2023 Database development of male breast cancer in Japan
2018 - 2021 Elucidation of the mrchanism of invasion in ductal carcinoma in situ
2015 - 2018 Isolation and functional analysis of blood circulating breast cancer cells by improved telome scan

Show all

Papers (122)：

Chisaki Hao, Yoshiya Horimoto, Toshitaka Uomori, Akihiko Shiraishi, Gotaro Orihata, Hiroko Onagi, Takuo Hayashi, Junichiro Watanabe, Goro Kutomi. Granulomatous mastitis forming a well-defined large mass diagnosed by surgical excision: a case report. Surgical Case Reports. 2024
Yoshiya Horimoto, Hikari Jimbo, Yumiko Ishizuka, Noriko Nogami, Goro Kutomi, Junichiro Watanabe. Absolute lymphocyte count as a biomarker for best supportive care transition in metastatic breast cancer. BMJ supportive & palliative care. 2024
Rongrong Wu, Yoshiya Horimoto, Masanori Oshi, Matthew G K Benesch, Thaer Khoury, Kazuaki Takabe, Takashi Ishikawa. Emerging measurements for tumor-infiltrating lymphocytes in breast cancer. Japanese journal of clinical oncology. 2024. 54. 6. 620-629
Shiori Tohyama, Yoshiya Horimoto, Yumiko Ushiyama, Ryoko Semba, Shiori Hotchi, Naomi Sugano, Kanako Ogura, Fumi Murakami. A case of phyllodes tumor with rapid growth during pregnancy and lactation period: a case report. Surgical case reports. 2024. 10. 1. 98-98
Yoshiya Horimoto, Hiroko Onagi, Junichiro Watanabe, Takuo Hayashi. HER2 staining of breast cancer is reduced under the current protocol of Ventana PATHWAY anti-HER-2/neu (4B5). Pathology international. 2024. 74. 2. 99-101

ｍore...

MISC (43)：

植木優子, 饗場恵美子, 播野裕子, 市川佑一, 新行内芳明, 堀本義哉, 中井克也, 飯島耕太郎, 水野博司, 齊藤光江. 当院におけるインプラント再建の現状. 日本乳癌学会総会プログラム抄録集. 2020. 28回. 88-88
Yoshiya Horimoto, Emi Tokuda, Fumi Murakami, Katsuya Nakai, Hideo Shimizu, Mitsue Saito. MESENCHYMAL CIRCULATING TUMOUR CELL ANALYSIS TO PREDICT EFFICACY OF ERIBULIN FOR METASTATIC BREAST CANCER PATIENTS. BREAST. 2017. 36. S40-S41
佐伯春美, 梶野一徳, 堀本義哉, Wali Nadila, Thinzar Hlaing May, 大辻奈穂美, 樋野興夫. 子宮内膜癌におけるミスマッチ修復異常と腫瘍内浸潤リンパ球. 日本癌学会総会記事. 2017. 76回. P-1119
Akiko Ogiya, Kieko Yamazaki, Rie Horii, Tadahiko Shien, Yoshiya Horimoto, Norikazu Masuda, Touko Inao, Mitsuchika Hosoda, Naoko Ishida, Tomofumi Osako, et al. Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer (vol 24, pg 473, 2017). BREAST CANCER. 2017. 24. 4. 642-642
M. Saito, K. Iijima, K. Nakai, Y. Horimoto, M. Mori, T. Himuro, T. Uomori, F. Murakami, A. Arakawa, K. Sasai. Risk factors for locoregional recurrence after post-mastectomy radiation therapy (PMRT) and chemotherapy in patients with 4 or more metastatic nodes. BREAST. 2017. 32. S74-S75

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page